No specific shared molecular target identified for tenapanor + omeprazole

No specific shared molecular target identified for tenapanor + omeprazole is a clinical designation indicating the absence of a common biological target for these two medications. Tenapanor (Ibsrela) is a minimally absorbed small molecule that inhibits the Sodium-Hydrogen Exchanger 3 (NHE3), a transporter responsible for sodium absorption in the small intestine and colon (Source: FDA Label for Ibsrela; PubChem CID 57406853). Omeprazole (Prilosec) is a substituted benzimidazole that acts as a proton pump inhibitor by targeting the H+/K+-ATPase enzyme in the gastric mucosa (Source: StatPearls, Omeprazole; PubChem CID 4594). Because tenapanor acts locally in the gut lumen and omeprazole acts on gastric acid-producing cells, they utilize distinct physiological pathways. Clinical pharmacology studies have demonstrated that the elevated gastric pH caused by omeprazole does not alter the pharmacodynamics or the local inhibitory effect of tenapanor on NHE3 (Source: ClinicalTrials.gov, NCT02081560). Therefore, this phrase confirms that the therapeutic efficacy of tenapanor is independent of the acid-suppression mechanism of omeprazole. This lack of interaction is significant for patients with irritable bowel syndrome or chronic kidney disease who may require both treatments simultaneously.

Not applicable